Long-term antibody dynamics challenge the paradigm of lifelong homotypic immunity to dengue virus

J Jair Andrade (Department of Genetics, University of Cambridge) A Adrien Mitard de Girardier (Department of Genetics, University of Cambridge) A Angkana T. Huang (Department of Genetics) D Darunee Buddhari (Department of Virology) M Marco Hamins-Puertolas (School of Medicine, University of California) M Maria-Theresa Alera (Chong Hua Hospital) M Mary Noreen Chua (Chong Hua Hospital) T Taweewun Hunsawong (Department of Virology) D Derek A. T. Cummings (Department of Biology) S Stephen Thomas (Microbiology and Immunology, State University of New York Upstate Medical University) H Heather Friberg (Viral Diseases Branch, Walter Reed Army Institute of Research) J Jeffrey R. Currier (Viral Diseases Branch, Walter Reed Army Institute of Research) A Adam Waickman (Microbiology and Immunology, State University of New York Upstate Medical University) A Aaron Farmer (Department of Virology) I In-Kyu Yoon (International Vaccine Institute) K Kathryn Anderson (Microbiology and Immunology, State University of New York Upstate Medical University) A Alan L. Rothman (Laboratory of Viral Immunity and Pathogenesis, University of Rhode Island) H Henrik Salje

Abstract

Immunity following infection with the four dengue virus serotypes (DENV1-4) remains difficult to define. Reports of individuals being reinfected with the same serotype challenge the paradigm that infection induces lifelong homotypic immunity. However, the frequency of these events and their importance for shaping immune profiles remain unknown. Here, we used data from three cohorts (N = 4,268 total participants) in two highly endemic settings (Cebu, Philippines, and Kamphaeng Phet, Thailand), which included long-term follow-up of individuals (mean follow-up of 8.8, 1.9, and 5.0 y). These data allowed us to elucidate age-specific patterns of infection and immunity, and to quantify individual long-term antibody titer dynamics following infection. We formulated mathematical models to explain these patterns, allowing for the possibility of progressive loss of immunity to homotypic reinfection. At the individual level, we found that, in the absence of subsequent infection, antibody titers exhibit a steady long-term decay following incident infections (half-life of 7 to 8 y), with the rate of decay slowing with increasing age. At the population level, incorporating homotypic reinfection was required to explain the age-specific dynamics of infection and immunity observed in our cohorts. We estimated that in highly endemic settings such as the Philippines, 60% of individuals have been homotypically reinfected by the age of 40 y. Our findings highlight homotypic reinfections as a key feature of endemic DENV settings and suggest that vaccines mimicking natural infection might not be expected to provide lifelong protection against infection.

Article Details

Volume / Issue Vol. 123, Issue 22
Published June 02, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (18)

J

Jair Andrade

Department of Genetics, University of Cambridge

A

Adrien Mitard de Girardier

Department of Genetics, University of Cambridge

A

Angkana T. Huang

Department of Genetics

D

Darunee Buddhari

Department of Virology

M

Marco Hamins-Puertolas

School of Medicine, University of California

M

Maria-Theresa Alera

Chong Hua Hospital

M

Mary Noreen Chua

Chong Hua Hospital

T

Taweewun Hunsawong

Department of Virology

D

Derek A. T. Cummings

Department of Biology

S

Stephen Thomas

Microbiology and Immunology, State University of New York Upstate Medical University

H

Heather Friberg

Viral Diseases Branch, Walter Reed Army Institute of Research

J

Jeffrey R. Currier

Viral Diseases Branch, Walter Reed Army Institute of Research

A

Adam Waickman

Microbiology and Immunology, State University of New York Upstate Medical University

A

Aaron Farmer

Department of Virology

I

In-Kyu Yoon

International Vaccine Institute

K

Kathryn Anderson

Microbiology and Immunology, State University of New York Upstate Medical University

A

Alan L. Rothman

Laboratory of Viral Immunity and Pathogenesis, University of Rhode Island

H

Henrik Salje